UPB

SEC source: 0001193125-26-394318 · ownership.xml · nonDerivative · entry 1

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,563

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-394322 · ownership.xml · nonDerivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,942

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-394330 · ownership.xml · nonDerivative · entry 1

Deykin Aaron · CIK 0002031693 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,302

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-394324 · ownership.xml · nonDerivative · entry 1

Houghton Adam · CIK 0002031691 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,901

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-394325 · ownership.xml · nonDerivative · entry 1

Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,717

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-274119 · ownership.xml · nonDerivative · entry 1

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,048

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-274121 · ownership.xml · nonDerivative · entry 1

Deykin Aaron · CIK 0002031693 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,197

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · balance_after: Includes 1,405 shares of Common Stock previously acquired under the Issuer's 2024 Employee Stock Purchase Plan.

SEC source: 0001193125-26-274122 · ownership.xml · nonDerivative · entry 1

Houghton Adam · CIK 0002031691 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,601

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-274126 · ownership.xml · nonDerivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,795

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-274125 · ownership.xml · nonDerivative · entry 1

Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,812

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-268169 · ownership.xml · derivative · entry 1

Ruddy Marcella K. · CIK 0002023849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-268168 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-268167 · ownership.xml · derivative · entry 1

Fleming Harold Edward · CIK 0001857250 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.direct: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

SEC source: 0001193125-26-268165 · ownership.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-268166 · ownership.xml · derivative · entry 1

Beckman Daniella · CIK 0001513422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-268164 · ownership.xml · derivative · entry 1

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P.

SEC source: 0001193125-26-111121 · ownership.xml · nonDerivative · entry 1

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,525

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-111134 · ownership.xml · nonDerivative · entry 1

Deykin Aaron · CIK 0002031693 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,687

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-111105 · ownership.xml · nonDerivative · entry 1

Houghton Adam · CIK 0002031691 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,301

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-111138 · ownership.xml · nonDerivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,648

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-111124 · ownership.xml · nonDerivative · entry 1

Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,907

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-004756 · ownership.xml · derivative · entry 2

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004756 · ownership.xml · nonDerivative · entry 1

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004757 · ownership.xml · derivative · entry 2

Deykin Aaron · CIK 0002031693 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires 2036-01-01

F3 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004757 · ownership.xml · nonDerivative · entry 1

Deykin Aaron · CIK 0002031693 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,581

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

F2 · balance_after: Includes 1,581 shares of Common Stock previously acquired under the Issuer's 2024 Employee Stock Purchase Plan.

SEC source: 0001193125-26-004755 · ownership.xml · derivative · entry 2

Houghton Adam · CIK 0002031691 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004755 · ownership.xml · nonDerivative · entry 1

Houghton Adam · CIK 0002031691 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004758 · ownership.xml · derivative · entry 2

GRAY MICHAEL · CIK 0001271411 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,500

Underlying: Common Stock · 91,500 shares

Expires 2036-01-01

F2 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004758 · ownership.xml · nonDerivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,500

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004754 · ownership.xml · derivative · entry 2

Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-004754 · ownership.xml · nonDerivative · entry 1

Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-085382 · ownership.xml · derivative · entry 1

Ruddy Marcella K. · CIK 0002023849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-25-085373 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-25-085371 · ownership.xml · derivative · entry 1

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P.

SEC source: 0000950170-25-085381 · ownership.xml · derivative · entry 1

Beckman Daniella · CIK 0001513422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-25-085372 · ownership.xml · derivative · entry 1

Fleming Harold Edward · CIK 0001857250 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.direct: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

SEC source: 0000950170-25-085370 · ownership.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-25-016460 · ownership.xml · derivative · entry 1

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-02-05

F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-016466 · ownership.xml · derivative · entry 1

Deykin Aaron · CIK 0002031693 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 165,000 shares

Expires 2035-02-05

F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-016467 · ownership.xml · derivative · entry 1

Houghton Adam · CIK 0002031691 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2035-02-05

F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-016471 · ownership.xml · derivative · entry 1

Sutherland Everett Rand · CIK 0001852880 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2035-02-05

F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-016469 · ownership.xml · derivative · entry 1

GRAY MICHAEL · CIK 0001271411 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2035-02-05

F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-137213 · ownership.xml · derivative · entry 1

Ambrose Allison · CIK 0002047381 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-12-15

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on December 16, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-114802 · ownership.xml · derivative · entry 2

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 894,733 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date.

SEC source: 0000950170-24-114802 · ownership.xml · nonDerivative · entry 1

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 894,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date.

SEC source: 0000947871-24-000806 · ownership.xml · derivative · entry 8

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 789,833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.exercise_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.expiration_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.

F4 · ownership.nature: Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000806 · ownership.xml · derivative · entry 7

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 197,456 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.exercise_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.expiration_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("Advisors II") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits ("Chimovits"), each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000806 · ownership.xml · derivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,098,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.exercise_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.expiration_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.

F4 · ownership.nature: Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000806 · ownership.xml · derivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 524,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · price: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.exercise_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.expiration_date: Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("Advisors II") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits ("Chimovits"), each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000806 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,554,873

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.

F4 · ownership.nature: Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.